Impact of 24-month treatment with etanercept, adalimumab, or methotrexate on metabolic syndrome components in a cohort of 210 psoriatic arthritis patients

Title
Impact of 24-month treatment with etanercept, adalimumab, or methotrexate on metabolic syndrome components in a cohort of 210 psoriatic arthritis patients
Authors
Keywords
Adalimumab, Anti-TNF-α, Etanercept, Metabolic syndrome, Methotrexate, Psoriatic arthritis
Journal
CLINICAL RHEUMATOLOGY
Volume -, Issue -, Pages -
Publisher
Springer Nature
Online
2013-08-19
DOI
10.1007/s10067-013-2369-1

Ask authors/readers for more resources

Reprint

Contact the author

Discover Peeref hubs

Discuss science. Find collaborators. Network.

Join a conversation

Create your own webinar

Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.

Create Now